Agenus Inc. (AGEN) and Turning Point Therapeutics Inc. (NASDAQ:TPTX) Comparison side by side

Agenus Inc. (NASDAQ:AGEN) and Turning Point Therapeutics Inc. (NASDAQ:TPTX) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agenus Inc. 4 0.00 95.83M -0.98 0.00
Turning Point Therapeutics Inc. 58 0.00 21.57M -3.77 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Agenus Inc. and Turning Point Therapeutics Inc.


Table 2 demonstrates the return on assets, net margins and return on equity of Agenus Inc. and Turning Point Therapeutics Inc.

Net Margins Return on Equity Return on Assets
Agenus Inc. 2,452,400,450.40% 77.8% -65.8%
Turning Point Therapeutics Inc. 37,023,686.92% 0% 0%


The current Quick Ratio of Agenus Inc. is 0.8 while its Current Ratio is 0.8. Meanwhile, Turning Point Therapeutics Inc. has a Current Ratio of 36.6 while its Quick Ratio is 36.6. Turning Point Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than Agenus Inc.

Analyst Ratings

Agenus Inc. and Turning Point Therapeutics Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agenus Inc. 0 0 1 3.00
Turning Point Therapeutics Inc. 0 0 5 3.00

$6 is Agenus Inc.’s consensus target price while its potential upside is 61.29%. On the other hand, Turning Point Therapeutics Inc.’s potential upside is 17.36% and its consensus target price is $63.2. The results provided earlier shows that Agenus Inc. appears more favorable than Turning Point Therapeutics Inc., based on analyst opinion.

Institutional and Insider Ownership

Institutional investors held 36.1% of Agenus Inc. shares and 73.4% of Turning Point Therapeutics Inc. shares. About 24.18% of Agenus Inc.’s share are held by insiders. On the other hand, insiders held about 0.1% of Turning Point Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agenus Inc. -6.68% 6.83% 24.52% 41.16% 66.38% 64.29%
Turning Point Therapeutics Inc. -8.88% 17.66% 23% 39.9% 0% 77.27%

For the past year Agenus Inc.’s stock price has smaller growth than Turning Point Therapeutics Inc.


Agenus Inc. beats on 6 of the 10 factors Turning Point Therapeutics Inc.

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodyÂ’s immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.